Pricing Log in Create free account
Friday 6 November 2026 Export STVN’s income statement to Excel — free account

Stevanato Group S.p.A.

STVN Healthcare Medical Instruments & Supplies

Stevanato Group S.p.A.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 12.3% from fiscal 2024.

Revenue
+5.91%
EPS
+17.5%
Free cash flow
+4,089.9%
Total debt
+2.85%

Quarter to September 2026, against a year earlier

12.96 0.25 −1.89%
Market cap
$3.6B
P/E
22.4×
Fwd P/E
30.2×
Dividend yield
0.48%
F-score
5/9
Altman Z
4.48
Beneish M
−2.79
Dividend safety
63/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.56
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — 4 — 3 1 — —
Insider Ownership 82.08%

Capital & Financial Ratios $m

Size
Market Cap 3,610.00
Revenue ttm 1,446.19
Net income ttm 227.37
Free cash flow ttm (8.79)
Net debt Q 400.09
Valuation
P/E 22.38
Forward P/E 30.20
Price / sales 2.48
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.95
Financial health
Current ratio Q 1.73 (at or above 1.5: strong)
Debt / equity Q 0.30 (at or below 0.5: strong)
Interest coverage Q 23.63
Growth
Revenue growth Q +5.91% (above 0%: growing)
Operating income growth Q +12.70% (above 0%: growing)
EPS, this year +11.80%
EPS, next year A +7.56%
Revenue, next year A −5.53% (below 0%: weak)
EPS, past 5 yrs +9.21%
EPS, next 5 yrs A +12.03%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.8×, against a ten-year median of 5.0×; over the ten years it ranged from 2.8× in 2026 to 8.0× in 2023.
P/E against its own 10 years 0.07%
10-year low 10-year high
P/S against its own 10 years 0.07%
10-year low 10-year high
P/B against its own 10 years 0.07%
10-year low 10-year high
EV/Sales against its own 10 years 0.07%
10-year low 10-year high

Dividends raised 2 years running

Yield
0.48%
Annual rate
0.06
Payout ratio
10.7%
Growth, 2022–26
+4.13%/yr
  1. 0.05 ’22
  2. 0.06 ’23 +8
  3. 0.06 ’24 +0
  4. 0.06 ’25 +7
  5. 0.06 ’26 +2
paid change on the year, % Powerpack

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 80 108 160 145
Receivables 390 397 400 426
Inventory 276 265 303 347
Other 187 183 204 186
933 952 1,067 1,104
2023 2024 2025 Q'26
Payables 301 250 298 281
ST’ Debt 155 127 140 150
Other 133 113 143 142
622 517 606 638

Compound Annual Growth %

10y 5y 3y
Sales — 12.16% 9.00%
Cash Flow — 12.73% 43.80%
Earnings — 12.02% 1.68%
Book Value — 36.55% 17.03%

Earnings Trends EPS, adjusted, against the consensus

Sep 2026 Estimate 0.17 Actual 0.18

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Dec 2025 0.20 0.21 Beat by 0.01
Mar 2026 0.12 0.13 Beat by 0.01
Jun 2026 0.15 0.16 Beat by 0.01
Sep 2026 0.17 0.18 Beat by 0.01
Dec 2026 0.24 — Reports 3 March 2027

EPS $

Mar Jun Sep Dec Year
’26 0.12 0.09 0.18 — —
’25 0.11 0.12 0.15 0.20 0.58
’24 0.08 0.09 0.12 0.19 0.47
’23 0.12 0.14 0.15 0.18 0.60
’22 0.11 0.13 0.14 0.18 0.57
’21 0.18 0.17 0.08 0.20 0.63
’20 0.03 0.09 0.07 — 0.37
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 320 351 375 — —
’25 270 318 354 400 1,342
’24 256 280 306 353 1,195
’23 255 278 295 345 1,175
’22 238 249 247 302 1,036
’21 232 246 253 267 998
’20 150 178 184 — 756
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 88 36 65 — —
’25 105 59 60 99 324
’24 78 23 22 45 169
’23 40 27 36 10 114
’22 6 45 (7) 65 109
’21 7 65 20 66 158
’20 (10) 59 62 178 178
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 6 (39) 25 — —
’25 31 (15) (1) (1) 15
’24 (34) (50) (34) (50) (167)
’23 (98) (77) (107) (81) (364)
’22 (56) (34) (42) (15) (147)
’21 (20) 37 (13) 22 25
’20 (10) 59 62 76 68
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.9
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 601 756 998 1,036 1,175 1,195 1,342 1,446 +14.3% 1,268 1,382 1,512 +4.1%
Gross margin, % — — — 24.29 29.33 31.45 32.51 31.32 27.38 28.99 29.11 +4.7 pt
EBT — — — 62 110 196 198 205 173 214 234 +22.9%
EBT margin, % — — — 10.32 14.54 19.63 19.08 17.46 14.52 15.94 16.18 +5.6 pt
Net income — 0 — 44 110 196 198 205 173 214 227 n/m
Per share, $
Per share, $ Revenue — — — 2.27 3.14 3.95 3.92 4.43 4.41 4.92 5.29 +13.8%
Earnings — — — 0.17 0.37 0.63 0.57 0.60 0.47 0.58 0.59 +22.7%
Cash flow — — — 0.18 0.74 0.62 0.41 0.43 0.62 1.19 1.06 +36.9%
Capex — — — 0.00 (0.46) (0.52) (0.97) (1.80) (1.24) (1.13) (1.09) n/m
Free cash flow — — — 0.18 0.28 0.10 (0.56) (1.37) (0.62) 0.05 (0.03) (18.3%)
Book value — — — 1.12 1.47 3.94 3.96 4.63 5.60 6.16 6.72 +32.8%
Shares, m — — — 265 241 253 265 265 271 273 273 +0.5%
Valuation, ×
Valuation, × P/E — — — 38.33 38.33 35.45 31.23 45.03 45.40 34.69 22.38 38.4
P/S — — — 5.64 5.64 5.68 4.47 5.99 4.95 4.09 2.48 5.2
P/B — — — 10.31 10.31 5.70 4.41 5.74 3.89 3.27 1.95 6.2
EV/Sales — — — 5.95 5.95 5.46 4.42 6.29 5.25 4.37 2.75 5.4
EV/FCF — — — 16.05 16.05 215.94 (31.15) (20.32) (37.47) 401.67 (453.16) 80.1
Cash, $m
Cash, $m Operating cash flow — — — 48 178 158 109 114 169 324 289 +37.6%
Capex — — — (83) (110) (133) (256) (478) (336) (309) (298) +24.6%
Free cash flow — — — 48 68 25 (147) (364) (167) 15 (9) (17.9%)
Balance, $m
Balance, $m Working capital — — — 210 202 624 404 311 436 461 466 +14.0%
Net debt — — — 291 249 (225) (45) 352 363 373 400 +4.2%
Shareholders’ equity — — — 298 354 996 1,049 1,226 1,520 1,682 1,835 +33.4%
Returns, %
Returns, % ROA — — — 8.89 8.56 11.41 8.78 7.90 5.35 5.86 5.50 (3.0) pt
ROIC — — — 0.00 12.20 15.55 12.62 8.61 5.79 6.84 6.71 +6.8 pt
ROE — — — 12.98 27.50 23.54 14.72 13.86 9.28 9.88 9.22 (3.1) pt
People
People Employees — — — — 4,344 4,652 5,260 5,635 5,521 6,010 — +6.7%
Revenue/emp, $m — — — 0.00 0.17 0.21 0.20 0.21 0.22 0.22 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Stevanato Group S.p.A. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TFX Teleflex Incorporated $6.5B — (loss-making) 37.4× +28.88% (above 0%: growing) −17.33% (below 0%: shrinking) +220.14% (above 0%: growing) 58.16% 12.77% Compare
MMSI Merit Medical Systems, Inc. $5.4B 33.2× 30.7× +8.35% (above 0%: growing) +50.53% (above 0%: growing) +50.18% (above 0%: growing) 48.20% 14.12% Compare
MMED MiniMed Group, Inc. $5.1B — (loss-making) 27.8× — n/m −13.92% (below 0%: shrinking) 55.16% 0.47% Compare
ICUI ICU Medical, Inc. $4.2B 69.3× 48.8× +4.37% (above 0%: growing) n/m +292.20% (above 0%: growing) 41.89% 9.34% Compare
NVST Envista Holdings Corporation $4.0B 6.4× 21.5× +3.22% (above 0%: growing) n/m −6.48% (below 0%: shrinking) 57.93% 74.50% Compare
PLSE Pulse Biosciences, Inc $3.9B — (loss-making) — (loss-making) +359.30% (above 0%: growing) n/m −1,180.54% (below 0%: shrinking) 51.65% (6,149.87%) Compare
STVN Stevanato Group S.p.A. $3.6B 22.4× 30.2× +5.91% (above 0%: growing) +17.53% (above 0%: growing) +4,089.92% (above 0%: growing) 29.12% 18.51%
WRBY Warby Parker Inc. $3.2B 434× 208× +10.40% (above 0%: growing) −20.00% (below 0%: shrinking) −30.28% (below 0%: shrinking) 54.41% 1.45% Compare
ATRC AtriCure, Inc. $3.1B 199× 573× +15.03% (above 0%: growing) n/m −0.73% (below 0%: shrinking) 77.27% 2.82% Compare
Median of peers $4.1B 69.3× 37.4× +10.40% −17.33% −3.60% 54.79% 6.08%

All 53 Medical Instruments & Supplies stocks →

Stevanato Group S.p.A. (STVN) Latest News

4 Nov

Impact 3 · · MarketBeat

3 Nov

Impact 3 · · Moby
Impact 3 · · The Motley Fool transcript
Impact 3 · · GuruFocus.com
Impact 3 · · Business Wire

28 Oct

Impact 4 · · Insider Monkey

27 Oct

Impact 4 · · Business Wire
Impact 4 · · Business Wire

20 Oct

Impact 3 · · Business Wire

4 Sep

Impact 4 ·

1 Sep

Impact 3 ·

10 Aug

Impact 4 ·
Impact 3 ·

9 Aug

Impact 3 · · MarketBeat transcript

4 Aug

Impact 4 · transcript
Impact 3 · · The Motley Fool transcript
Impact 3 · · Moby transcript
Impact 3 ·
Impact 3 ·

30 Jul

Impact 4 ·

8 Jun

Impact 4 · · Business Wire

9 May

Impact 4 ·

8 May

Impact 4 · · The Motley Fool transcript
Impact 3 · · Moby

7 May

Impact 4 ·
Impact 3 · · Business Wire

30 Apr

Impact 3 · · Zacks

27 Apr

Impact 3 · · Insider Monkey

25 Apr

Impact 4 · · Simply Wall St.

1 Apr

Impact 3 · · Insider Monkey

STVN metrics, ten years each

stockrow.com/STVN · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com